Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial

May 04, 2023 By The ASCO Post Staff

Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy significantly prolonged progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of germline BRCA mutation or homologous recombination deficiency biomarker status. Here, Dr. Matulonis details the final phase III findings on overall survival and the long-term safety of niraparib in this population.

Related Content